公司概述
Quipt Home Medical Corp. operates as a provider of durable medical equipment and supplies within the United States market, specifically focusing on therapeutic solutions such as nebulizers, invasive ventilation systems, and treatments for sleep apnea and PAP therapy. The company functions within the Healthcare sector and the Medical Distribution industry, a space characterized by the logistics and supply chain management of essential medical goods to patients and facilities. As of the latest reporting period, the entity maintains a market capitalization of $162.30M and generates annual revenue totaling $264.97M, supporting an operational workforce of 1500 employees. These financial figures indicate a mid-sized market position where significant revenue generation occurs despite a relatively modest market capitalization, suggesting a business model that prioritizes volume and distribution reach over immediate equity valuation expansion.
财务健康
Quipt Home Medical Corp. reported a trailing twelve-month revenue of $264.97M alongside a net income of -$10,670,000, while maintaining an EBITDA of $43.58M, a disparity that reveals a substantial cost structure burden impacting bottom-line profitability. The company demonstrates robust financial flexibility through a free cash flow of $44.54M, indicating the ability to generate cash from operations sufficient to cover capital expenditures and potentially fund internal initiatives without relying on external financing. Operating margins stand at 1.5%, while the gross margin is reported at 72.4% and the profit margin is -4.0%, illustrating that high gross profitability is heavily eroded by operating expenses, resulting in an overall loss on sales. In terms of leverage, total cash on hand of $10.54M is significantly lower than the total debt of $115.63M, reflected in a debt-to-equity ratio of 102.33, which characterizes a highly leveraged balance sheet. Short-term liquidity is assessed as tight with a current ratio of 1.04, suggesting that current assets barely exceed current liabilities and leaving limited buffer for immediate obligations. Furthermore, the Return on Equity is -9.3% and the Return on Assets is -0.8%, metrics that reveal management has yet to achieve positive returns on shareholder capital or asset base during this period.
估值评估
The valuation profile presents a trailing P/E ratio of N/A due to negative earnings, contrasted sharply with a forward P/E of 182.50, implying that the market is pricing in a complete turnaround in earnings trajectory expected in future periods. The price-to-book ratio stands at 1.59, indicating that the stock trades at a premium relative to its book value, likely reflecting investor confidence in the asset base and future operational improvements despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 0.61 and an EV/EBITDA of 6.41 suggest that the company is valued based on sales multiples and enterprise cash generation rather than current profitability, which is common for turnaround candidates or capital-intensive distributors. The stock's trading range over the last 52 weeks spans from a low of $1.35 to a high of $3.65, providing a context for current price positioning relative to historical volatility. The beta value of 0.49 indicates that the stock exhibits lower price volatility compared to the broader market, moving with less intensity than the general equity index.
Growth & Income
Quipt Home Medical Corp. achieved a revenue growth rate of 32.0% year-over-year, while earnings growth is listed as N/A, implying that revenue expansion is currently decoupled from immediate profitability improvements. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the entity retains all earnings rather than distributing them to shareholders, a strategy often employed to preserve cash for debt reduction or reinvestment in the business. This non-dividend status means the company reinvests its operational cash flows into growth initiatives rather than providing income to investors. The overall growth and income profile is defined by rapid top-line expansion accompanied by significant leverage and the absence of dividend income, highlighting a high-risk, high-reward capital allocation approach typical of companies in the early stages of a profitability recovery.